USPTO serial 79440214
MISBA
Reviewed by CopyMark Law Group
Status 661
- Filing date
- Status date
- Registration date
- —
- Examiner
- MACFARLANE, JAMES W
- Law office
- TMEG LAW OFFICE 104
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with MISBA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Rebecca Liebowitz
Rebecca Liebowitz Venable LLPP.O. Box 34385Washington, DC 20043United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemicals for scientific purposes; chemicals for use in research; chemicals, enzymes, and biological preparations in the nature of DNA and RNA for research use; chemicals for use in the preparation and creation of DNA and RNA; enzymes for use in the preparation and creation of DNA and RNA; molecular biology research tools in the nature of biological, chemical and biochemical reagents for research use | ACTIVE | — |
| 005 | Pharmaceutical preparations for the treatment and prevention of ophthalmological conditions, hearing loss, hematologic diseases, immune response disorders, autoimmune conditions and disorders, neurological disorders, neurodegenerative disorders, psychiatric disorders, respiratory diseases, fibrosis, hepatic diseases, renal diseases, diseases of the pancreas, metabolic diseases, genetic conditions, cancer, infectious diseases and cardiovascular diseases; medical and veterinary preparations for therapeutic purposes, for the treatment and prevention of ophthalmological conditions, hearing loss, hematologic diseases, immune response disorders, autoimmune conditions and disorders, neurological disorders, neurodegenerative disorders, psychiatric disorders, respiratory diseases, fibrosis, hepatic diseases, renal diseases, diseases of the pancreas, metabolic diseases, genetic conditions, cancer, infectious diseases and cardiovascular diseases; biological, chemical and biochemical reagents for medical use; DNA, RNA, oligonucleotides, and polynucleotides for medical and veterinary use; gene editing enzymes for medical and veterinary use; medical and veterinary preparations containing therapeutic DNA and RNA, for the treatment and prevention of ophthalmological conditions, hearing loss, hematologic diseases, immune response disorders, autoimmune conditions and disorders, neurological disorders, neurodegenerative disorders, psychiatric disorders, respiratory diseases, fibrosis, hepatic diseases, renal diseases, diseases of the pancreas, metabolic diseases, genetic conditions, cancer, infectious diseases and cardiovascular diseases; biological, chemical and biochemical reagents for medical or veterinary use | ACTIVE | — |
| 042 | Scientific and technological services and research and design relating thereto, namely scientific research services in the field of genomics; medical and veterinary research services, including the manipulation of biological reagents to be used for medical, veterinary or therapeutic purposes; chemical and biological analysis and research services; medical and scientific research into DNA and RNA; medical and scientific research and product development into regarding the creation of DNA and RNA; medical and scientific research and product development services in the field of the manufacture of synthetic DNA, RNA, genes and oligonucleotides for others; medical and scientific research, product development, product testing and research laboratory analysis services in the field of genomics, DNA and RNA sequencing, gene synthesis, gene identification, gene cloning, gene expression, and gene mapping; scientific and medical research in the fields of molecular biology, next generation sequencing, high-throughput sequencing, and bioinformatics; medical and scientific research in the fields of DNA and RNA modelling services; gene engineering services; medical and scientific research and product development services regarding the creation of genome libraries or collections of biologicals including chemicals and compounds; medical and scientific research and product development services in regarding creating libraries or collections of normal and mutated genes; scientific services relating to the discovery and the preclinical and clinical development of therapeutic products; medical and scientific research consultancy | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 12, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 12, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 12, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 4, 2026 | RFNT | REFUSAL PROCESSED BY IB | — |
| May 15, 2026 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| May 14, 2026 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Mar 31, 2026 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Mar 30, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 30, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 4, 2026 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jan 4, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 25, 2025 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |